Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Objective

To assess the effect of statins compared with placebo on the risk of developing hypertransaminasemia.

Patients and methods

We performed a systematic review of electronic databases and included articles published between January 1, 1965, and April 10, 2017. Randomized clinical trials (RCTs) comparing statins vs placebo were included. Odds ratios (ORs) were pooled in random-effect meta-analyses according to established methods recommended by the Cochrane Collaboration.

Results

Seventy-three eligible RCTs, comprising 123,051 patients, were identified. Statins associated with a significantly risk of hypertransaminasemia (OR 1.45; 95% confidence interval [CI], 1.24-1.69; P<.001). Atorvastatin showed the highest odds (OR 2.66; 95% CI, 1.74-4.06; P<.0

SUBMITTER: Villani R 

PROVIDER: S-EPMC6544559 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature